StockData
Nasus Pharma Ltd logo

Nasus Pharma Ltd (NSRX) income statement

NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 25, 2026Score 6/30
$2.70+0.09 (+3.45%)

Close on Nov 18, 2026Market cap $24.34MP/E –Yield –

Nasus Pharma Ltd income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin
–
Operating margin
-0.4%
Net margin
-0.5%
Return on equity, FY2025
2637.8%

Financial strength

Current ratio
8.77
Debt to equity
–
Debt to assets
–
Cash to current liabilities
556.8%

Valuation

P/E ratio
–
Price to sales
0.02
Price to book
2.21
Dividend yield
–

See a number that looks wrong?